Novartis to acquire Calypso Biotech and CALY-002 therapeutic antibody
Novartis will acquire Calypso Biotech, a developer of Interleukin15 (IL-15) targeted therapies, for US$250 million plus a further $175 million based on the achievement of certain predetermined milestones.